Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

For me, that would be anticipating too much. This reminds me of the efficacy vs. Efficacy debate. With dosing at less than efficacious ranges, we should set our targets on efficacy (Serum tumor markers, p21, restaging etc.) When we get to higher doses (like cohort 6,7 and 8) we are at least in the efficacy range, but not optimal dosing - later phases will also allow for more frequent dosing. In phase 2, I think it is critical to show Efficacy (extended life).

In next week's presentation, I'm hoping for more restagings (actual changes, not just new measurements), p21 confirmation, and more patients requesting additional treatments. Also, I hope we get all this AND confirmation that cohort 7 began dosing with the statement no SAE/DLTs to date. Oh, and I hope he mentions a few more cancer types that K has been showing efficacy against.

That would be a most excellent update for me.